Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.74 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.74 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 9/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.49 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 7/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.46 |
| ▸ | MIF | P14174 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 4/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | RAB9A | P51151 | 5/20 | 0.44 |
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | CASP1 | P29466 | 2/20 | 0.44 |
| ▸ | CASP7 | P55210 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | GLA | P06280 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30165795 | 1.00 | PIK3CD (0.74) | PIK3CDPIK3CBALKMAPTMCL1 | |
| SCHEMBL4586333 | 0.85 | PIK3CD (0.74) | PIK3CDPIK3CBALKMAPTHPGD | |
| SCHEMBL29427470 | 0.85 | PIK3CD (1.00) | PIK3CDPIK3CBALKMAPTMCL1 | |
| SCHEMBL592311 | 0.85 | PIK3CD (1.00) | PIK3CDPIK3CBALKMAPTMCL1 | |
| SCHEMBL29524563 | 0.85 | PIK3CD (1.00) | PIK3CDPIK3CBALKMAPTMCL1 | |
| SCHEMBL2623784 | 0.85 | PIK3CD (0.74) | PIK3CDPIK3CBALKMAPTAPP | |
| SCHEMBL14753532 | 0.85 | PIK3CD (0.74) | PIK3CDPIK3CBALKMAPTAPP | |
| SCHEMBL24910436 | 0.84 | PIK3CD (0.54) | PIK3CDPIK3CBALKMAPTMCL1 | |
| SCHEMBL30674288 | 0.83 | PIK3CD (0.71) | PIK3CDPIK3CBALKMAPTAPP | |
| SCHEMBL12040001 | 0.83 | PIK3CD (0.71) | PIK3CDPIK3CBALKMAPTAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250002994-A1 | TERTIARY AMINE SUBSTITUTED COUMARIN COMPOUNDS AND USES AS FLUORESCENT LABELS | ILLUMINA CAMBRIDGE LIMITED (GB) | 2025-01-02 | — | — | US | disclosed |
| EP-3697778-B1 | SECONDARY AMINE-SUBSTITUTED COUMARIN COMPOUNDS AND THEIR USES AS FLUORESCENT LABELS | ILLUMINA CAMBRIDGE LTD (GB) | 2024-12-04 | — | — | EP | disclosed |
| US-12110546-B2 | Tertiary amine substituted coumarin compounds and uses as fluorescent labels | ILLUMINA CAMBRIDGE LIMITED (GB) | 2024-10-08 | — | — | US | disclosed |
| US-11884825-B2 | Exocyclic amine substituted coumarin compounds and uses as fluorescent labels | ILLUMINA CAMBRIDGE LIMITED (GB) | 2024-01-30 | — | — | US | disclosed |
| US-11858923-B2 | Secondary amine-substituted coumarin compounds and their uses as fluorescent labels | ILLUMINA CAMBRIDGE LIMITED (GB) | 2024-01-02 | — | — | US | disclosed |
| US-11858923-B2 | Secondary amine-substituted coumarin compounds and their uses as fluorescent labels | ILLUMINA CAMBRIDGE LIMITED (GB) | 2024-01-02 | — | — | US | disclosed |
| US-11858923-B2 | Secondary amine-substituted coumarin compounds and their uses as fluorescent labels | ILLUMINA CAMBRIDGE LIMITED (GB) | 2024-01-02 | — | — | US | disclosed |
| US-20230025669-A1 | SECONDARY AMINE-SUBSTITUTED COUMARIN COMPOUNDS AND THEIR USES AS FLUORESCENT LABELS | ILLUMINA CAMBRIDGE LIMITED (GB) | 2023-01-26 | — | — | US | disclosed |
| US-20230025669-A1 | SECONDARY AMINE-SUBSTITUTED COUMARIN COMPOUNDS AND THEIR USES AS FLUORESCENT LABELS | ILLUMINA CAMBRIDGE LIMITED (GB) | 2023-01-26 | — | — | US | disclosed |
| US-20230022437-A1 | EXOCYCLIC AMINE SUBSTITUTED COUMARIN COMPOUNDS AND USES AS FLUORESCENT LABELS | ILLUMINA CAMBRIDGE LIMITED (GB) | 2023-01-26 | — | — | US | disclosed |
| WO-2019077331-A1 | SECONDARY AMINE-SUBSTITUTED COUMARIN COMPOUNDS AND THEIR USES AS FLUORESCENT LABELS | ILLUMINA CAMBRIDGE LIMITED (GB) | 2019-04-25 | — | — | WO | disclosed |
| US-9617268-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617268-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617268-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-20150119380-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. HOFFMANN-LA ROCHE AG (CH) | 2015-04-30 | — | — | US | disclosed |
| US-20150119380-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. HOFFMANN-LA ROCHE AG (CH) | 2015-04-30 | — | — | US | disclosed |
| US-20150119380-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. HOFFMANN-LA ROCHE AG (CH) | 2015-04-30 | — | — | US | disclosed |
| EP-2797592-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC Therapeutics, Inc. (US) | 2014-11-05 | — | — | EP | disclosed |
| WO-2013101974-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2013-07-04 | — | — | WO | disclosed |
| WO-2013101974-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2013-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858923-B2 | Secondary amine-substituted coumarin compounds and their uses as fluorescent labels | FBL, NSUN2, DNA2 | PIK3CD 4323/4885PIK3CB 3062/4885ALK 1976/4885 |
| US-12110546-B2 | Tertiary amine substituted coumarin compounds and uses as fluorescent labels | FBL, NAT10, DNMT3A | PIK3CD 4043/4885PIK3CB 2775/4885ALK 2193/4885 |
| US-20230025669-A1 | SECONDARY AMINE-SUBSTITUTED COUMARIN COMPOUNDS AND THEIR USES AS FLUORESCENT LABELS | FBL, NSUN2, DNA2 | PIK3CD 4323/4885PIK3CB 3062/4885ALK 1976/4885 |
| US-20150119380-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, RBM17, RBM22 | PIK3CD 3763/4885PIK3CB 3181/4885ALK 4482/4885 |
| US-20250002994-A1 | TERTIARY AMINE SUBSTITUTED COUMARIN COMPOUNDS AND USES AS FLUORESCENT LABELS | FBL, NAT10, DNMT3A | PIK3CD 4043/4885PIK3CB 2775/4885ALK 2193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.